JP2015530877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015530877A5 JP2015530877A5 JP2015525857A JP2015525857A JP2015530877A5 JP 2015530877 A5 JP2015530877 A5 JP 2015530877A5 JP 2015525857 A JP2015525857 A JP 2015525857A JP 2015525857 A JP2015525857 A JP 2015525857A JP 2015530877 A5 JP2015530877 A5 JP 2015530877A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- response
- gene
- patient
- adaptive immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 230000033289 adaptive immune response Effects 0.000 claims 12
- 230000004044 response Effects 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 238000011282 treatment Methods 0.000 claims 9
- 230000001506 immunosuppresive effect Effects 0.000 claims 8
- 230000000259 anti-tumor effect Effects 0.000 claims 7
- 230000014509 gene expression Effects 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 4
- 230000008629 immune suppression Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 230000003796 beauty Effects 0.000 claims 2
- 230000004043 responsiveness Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000013211 curve analysis Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305975.0 | 2012-08-06 | ||
| EP12305975 | 2012-08-06 | ||
| PCT/EP2013/066425 WO2014023706A1 (en) | 2012-08-06 | 2013-08-05 | Methods and kits for screening patients with a cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019131862A Division JP6995091B2 (ja) | 2012-08-06 | 2019-07-17 | 癌患者をスクリーニングするための方法及びキット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015530877A JP2015530877A (ja) | 2015-10-29 |
| JP2015530877A5 true JP2015530877A5 (enExample) | 2016-09-23 |
| JP6559566B2 JP6559566B2 (ja) | 2019-08-14 |
Family
ID=46762994
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525857A Active JP6559566B2 (ja) | 2012-08-06 | 2013-08-05 | 癌患者をスクリーニングするための方法及びキット |
| JP2019131862A Active JP6995091B2 (ja) | 2012-08-06 | 2019-07-17 | 癌患者をスクリーニングするための方法及びキット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019131862A Active JP6995091B2 (ja) | 2012-08-06 | 2019-07-17 | 癌患者をスクリーニングするための方法及びキット |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150218650A1 (enExample) |
| EP (2) | EP2880180B1 (enExample) |
| JP (2) | JP6559566B2 (enExample) |
| AU (1) | AU2013301609B2 (enExample) |
| CA (1) | CA2881389C (enExample) |
| DK (1) | DK2880180T3 (enExample) |
| ES (1) | ES2702722T3 (enExample) |
| LT (1) | LT2880180T (enExample) |
| PL (1) | PL2880180T3 (enExample) |
| PT (1) | PT2880180T (enExample) |
| SG (1) | SG11201500922RA (enExample) |
| TR (1) | TR201819211T4 (enExample) |
| WO (1) | WO2014023706A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| SG10202005315SA (en) * | 2014-08-19 | 2020-07-29 | Nat Univ Corporation Okayama Univ | Agent for treating and/or preventing diseases associated with immune abnormalities by combining biguanide antidiabetic drug with immunosuppressive factor blocking agent or costimulatory receptor agonist |
| EP3240908A2 (en) * | 2014-12-30 | 2017-11-08 | F. Hoffmann-La Roche AG | Methods and compositions for prognosis and treatment of cancers |
| JP7281903B2 (ja) * | 2016-05-09 | 2023-05-26 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | 固形腫瘍を有する患者をクラス分けするための方法 |
| MX2019010295A (es) | 2017-03-01 | 2019-11-21 | Genentech Inc | Métodos de diagnóstico y terapéuticos para el cáncer. |
| KR102350221B1 (ko) | 2018-03-22 | 2022-01-14 | 스미또모 덴꼬오 하드메탈 가부시끼가이샤 | 표면 피복 절삭 공구 및 그 제조 방법 |
| EP3861137A4 (en) * | 2018-10-01 | 2022-07-13 | Nantomics, LLC | Evidence based selection of patients for clinical trials using histopathology |
| CN114072676B (zh) | 2019-06-03 | 2024-07-12 | 法国国家卫生及研究医学协会 | 调节治疗方案的方法 |
| WO2021092071A1 (en) | 2019-11-07 | 2021-05-14 | Oncxerna Therapeutics, Inc. | Classification of tumor microenvironments |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| EP4172621A1 (en) | 2020-06-30 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
| JP7741831B2 (ja) | 2020-06-30 | 2025-09-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法 |
| US20250035635A1 (en) | 2022-03-17 | 2025-01-30 | Institut National De La Sante Et De La Recherche Medicale | Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888278A (en) | 1985-10-22 | 1989-12-19 | University Of Massachusetts Medical Center | In-situ hybridization to detect nucleic acid sequences in morphologically intact cells |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US6280929B1 (en) | 1986-01-16 | 2001-08-28 | The Regents Of The University Of California | Method of detecting genetic translocations identified with chromosomal abnormalities |
| US5427932A (en) | 1991-04-09 | 1995-06-27 | Reagents Of The University Of California | Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using |
| US5472842A (en) | 1993-10-06 | 1995-12-05 | The Regents Of The University Of California | Detection of amplified or deleted chromosomal regions |
| US6942970B2 (en) | 2000-09-14 | 2005-09-13 | Zymed Laboratories, Inc. | Identifying subjects suitable for topoisomerase II inhibitor treatment |
| JP2002363169A (ja) * | 2001-06-08 | 2002-12-18 | Fujiyakuhin Co Ltd | 抗腫瘍活性を有する複素環化合物 |
| US7711492B2 (en) * | 2003-09-03 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for diagnosing lymphoma types |
| US20110152115A1 (en) * | 2003-09-03 | 2011-06-23 | The United States of America, as represented by the Secretary, Department of Health and | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| EP1893241A2 (en) | 2005-04-28 | 2008-03-05 | Ventana Medical Systems, Inc. | Fluorescent nanoparticles conjugated to antibodies via a peg linker |
| US20060246523A1 (en) | 2005-04-28 | 2006-11-02 | Christopher Bieniarz | Antibody conjugates |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| CN104090095B (zh) | 2005-11-23 | 2016-06-01 | 文塔纳医疗系统公司 | 分子缀合物 |
| US20110070582A1 (en) * | 2008-11-03 | 2011-03-24 | Source Precision Medicine, Inc. d/b/d Source MDX | Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects |
| ES2816625T3 (es) * | 2010-09-24 | 2021-04-05 | Niels Grabe | Medios y métodos para la predicción de la respuesta a un tratamiento de un paciente con cáncer |
| EP2663650B1 (en) * | 2011-01-11 | 2016-11-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the outcome of a cancer in a patient by analysing gene expression |
-
2013
- 2013-08-05 LT LTEP13745117.5T patent/LT2880180T/lt unknown
- 2013-08-05 ES ES13745117T patent/ES2702722T3/es active Active
- 2013-08-05 TR TR2018/19211T patent/TR201819211T4/tr unknown
- 2013-08-05 JP JP2015525857A patent/JP6559566B2/ja active Active
- 2013-08-05 AU AU2013301609A patent/AU2013301609B2/en not_active Ceased
- 2013-08-05 EP EP13745117.5A patent/EP2880180B1/en active Active
- 2013-08-05 EP EP18196198.8A patent/EP3470531A1/en not_active Withdrawn
- 2013-08-05 DK DK13745117.5T patent/DK2880180T3/en active
- 2013-08-05 CA CA2881389A patent/CA2881389C/en active Active
- 2013-08-05 WO PCT/EP2013/066425 patent/WO2014023706A1/en not_active Ceased
- 2013-08-05 PT PT13745117T patent/PT2880180T/pt unknown
- 2013-08-05 US US14/420,053 patent/US20150218650A1/en not_active Abandoned
- 2013-08-05 PL PL13745117T patent/PL2880180T3/pl unknown
- 2013-08-05 SG SG11201500922RA patent/SG11201500922RA/en unknown
-
2019
- 2019-07-17 JP JP2019131862A patent/JP6995091B2/ja active Active
-
2020
- 2020-06-09 US US16/896,736 patent/US20200299784A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018007872A9 (en) | Biomarkers for inflammatory bowel disease | |
| JP2014521308A5 (enExample) | ||
| EP4417706A3 (en) | Method for diagnosis and prognosis of chronic heart failure | |
| JP2016507233A5 (enExample) | ||
| CA2881389C (en) | Methods and kits for screening patients with a cancer | |
| MX2017014381A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| JP2016500110A5 (enExample) | ||
| JP2013066474A5 (enExample) | ||
| EP3236262A3 (en) | Surrogate functional diagnostics test for cancer | |
| JP2019176880A5 (enExample) | ||
| JP2020502498A5 (enExample) | ||
| JP2015210268A5 (enExample) | ||
| JP2018504909A5 (enExample) | ||
| RU2012103932A (ru) | Биомаркер для отбора пациентов и связанные с ним способы | |
| JP2015530094A5 (enExample) | ||
| Mourino-Alvarez et al. | Proteomic characterization of EPCs and CECs “in vivo” from acute coronary syndrome patients and control subjects | |
| RU2013119459A (ru) | Комплекс ipp в качестве маркера лечения эрлотинибом | |
| Huang et al. | Gene expression changes in the human diaphragm after cardiothoracic surgery | |
| Hegade et al. | Patient Experience and Characteristics of Cholestatic Pruritus in the UK-PBC Research Cohort: 322 | |
| JP2016010346A5 (enExample) | ||
| RU2016129060A (ru) | Биомаркеры для оценки ответа на лечение нвv | |
| CN103468825A (zh) | 一种用于鹅性别鉴定的引物、试剂盒及方法 | |
| JP2012205590A5 (enExample) | ||
| Holmes et al. | Bayesian immunological model development from the literature: example investigation of recent thymic emigrants | |
| Mursalimova | INFLUENCE OF INDIVIDUALLY-TYPOLOGICAL FEATURES OF THE GYMNASTS ON THE RELIABILITY OF COMPETITIVE ACTIVITY |